Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: The ANSWER cohort study
Rheumatology 2025 Doi: 10.1093/rheumatology/keaf552 Epub ahead of print
Nozaki et al. showed that JAK inhibitor treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction, although TNF inhibitors remain a standard option. Nozaki et al. evaluated the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor-prognosis factors (PPFs).